Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
23,500
+450 (1.95%)
At close: Feb 27, 2026
542.95%
Market Cap 1.05T
Revenue (ttm) 46.65B
Net Income (ttm) 16.75B
Shares Out 44.89M
EPS (ttm) 1,513.84
PE Ratio 15.52
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,086,104
Average Volume 1,618,934
Open 23,850
Previous Close 23,050
Day's Range 22,700 - 24,450
52-Week Range 3,138 - 28,900
Beta n/a
RSI 62.24
Earnings Date Mar 13, 2026

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.